{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:30:46Z","timestamp":1788449446425,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejca.2025.116066","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T22:25:17Z","timestamp":1760999117000},"page":"116066","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Real-world immunotherapy outcomes in unresectable peritoneal mesothelioma: A French experience"],"prefix":"10.1016","volume":"231","author":[{"given":"Cristina","family":"Smolenschi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Boileve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Vaflard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4534-8783","authenticated-orcid":false,"given":"Sarah","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Sourouille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Valery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2869-7551","authenticated-orcid":false,"given":"Antoine","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeva","family":"Lion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siriane","family":"Anglaret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Camilleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximiliano","family":"Gelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Diebakate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Megherbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3804-3554","authenticated-orcid":false,"given":"Anthony","family":"Tarabay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonor","family":"Benhaim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Fernandez-De-Sevilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pudlarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina Cristina","family":"Fuerea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Boige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejca.2025.116066_bib1","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ejca.2012.02.047","article-title":"Rare thoracic cancers, including peritoneum mesothelioma","volume":"48","author":"Siesling","year":"2012","journal-title":"Eur J Cancer"},{"issue":"33","key":"10.1016\/j.ejca.2025.116066_bib2","doi-asserted-by":"crossref","first-page":"13618","DOI":"10.1073\/pnas.1105887108","article-title":"Erionite exposure in north dakota and turkish villages with mesothelioma","volume":"108","author":"Carbone","year":"2011","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"10.1016\/j.ejca.2025.116066_bib3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/jcp.22724","article-title":"Malignant mesothelioma: facts, myths, and hypotheses","volume":"227","author":"Carbone","year":"2012","journal-title":"J Cell Physiol"},{"issue":"5","key":"10.1016\/j.ejca.2025.116066_bib4","first-page":"402","article-title":"Mesothelioma: scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA a cancer journal clinicians"},{"issue":"11","key":"10.1016\/j.ejca.2025.116066_bib5","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/s41379-020-0588-y","article-title":"Molecular characterization of diffuse malignant peritoneal mesothelioma","volume":"33","author":"Hung","year":"2020","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.ejca.2025.116066_bib6","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s10238-024-01342-y","article-title":"Genomic characterization and detection of potential therapeutic targets for peritoneal mesothelioma in current practice","volume":"24","author":"van Kooten","year":"2024","journal-title":"Clin Exp Med"},{"issue":"36","key":"10.1016\/j.ejca.2025.116066_bib7","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience","volume":"27","author":"Yan","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2025.116066_bib8","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1245\/s10434-014-3978-x","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis","volume":"22","author":"Helm","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.116066_bib9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3816\/CLC.2005.n.020","article-title":"Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program","volume":"7","author":"J\u00e4nne","year":"2005","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2025.116066_bib10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejso.2020.02.011","article-title":"Peritoneal mesothelioma: PSOGI\/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"47","author":"Kusamura","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2025.116066_bib11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.lungcan.2008.08.013","article-title":"Malignant peritoneal mesothelioma-Results from the international expanded access program using pemetrexed alone or in combination with a platinum agent","volume":"64","author":"Carteni","year":"2009","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2025.116066_bib12","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2025.116066_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.19934","article-title":"Clinical efficacy of immune checkpoint inhibitors in patients with advanced malignant peritoneal mesothelioma","volume":"4","author":"Raghav","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.ejca.2025.116066_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.2526","article-title":"Clinical outcomes associated with pembrolizumab monotherapy among adults with diffuse malignant peritoneal mesothelioma","volume":"6","author":"Marmarelis","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.ejca.2025.116066_bib15","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/JLB.5MIR0720-271RR","article-title":"Specialized immune responses in the peritoneal cavity and omentum","volume":"109","author":"Liu","year":"2021","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.ejca.2025.116066_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.humpath.2019.02.001","article-title":"Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by dako PD-L1 22C3 pharmdx and dako PD-L1 28-8 pharmdx assays","volume":"87","author":"Chapel","year":"2019","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ejca.2025.116066_bib17","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5804230","article-title":"Complex immune contextures characterise malignant peritoneal mesothelioma: loss of adaptive immunological signature in the more aggressive histological types","volume":"2018","author":"Tazzari","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1016\/j.ejca.2025.116066_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.585079","article-title":"Apatinib mesylate inhibits the proliferation and metastasis of epithelioid malignant peritoneal mesothelioma in vitro and in vivo","volume":"10","author":"Yang","year":"2020","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2025.116066_bib19","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1054\/bjoc.2001.1997","article-title":"Angiogenesis is an independent prognostic factor in malignant mesothelioma","volume":"85","author":"Edwards","year":"2001","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2025.116066_bib20","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2025.116066_bib21","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1158\/2159-8290.CD-21-0331","article-title":"Efficacy, safety, and biomarker analysis of combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) blockade in advanced malignant peritoneal mesothelioma","volume":"11","author":"Raghav","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2025.116066_bib22","unstructured":"\u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-and-ipilimumab-unresectable-malignant-pleural-mesothelioma\u3009."},{"key":"10.1016\/j.ejca.2025.116066_bib23","unstructured":"\u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/opdivo\u3009."},{"issue":"10272","key":"10.1016\/j.ejca.2025.116066_bib24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.116066_bib25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3389\/fonc.2020.00187","article-title":"Immunotherapy in malignant pleural mesothelioma","volume":"10","author":"De Gooijer","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2025.116066_bib26","doi-asserted-by":"crossref","DOI":"10.21037\/pcm-21-12","article-title":"Asbestos-induced chronic inflammation in malignant pleural mesothelioma and related therapeutic approaches\u2014a narrative review","volume":"4","author":"Zolondick","year":"2021","journal-title":"Precis Cancer Med"},{"issue":"12","key":"10.1016\/j.ejca.2025.116066_bib27","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/oem.2006.031724","article-title":"Asbestos exposure and differences in occurrence of peritoneal mesothelioma between men and women across countries","volume":"64","author":"Burdorf","year":"2007","journal-title":"Occup Environ Med"},{"issue":"11","key":"10.1016\/j.ejca.2025.116066_bib28","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41571-022-00675-5","article-title":"Advances in the management of peritoneal malignancies","volume":"19","author":"Kepenekian","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2025.116066_bib29","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/028418519103200503","article-title":"Peritoneal mesothelioma. Radiologic appearances correlated with histology","volume":"32","author":"Ros","year":"1991","journal-title":"Acta Radio"},{"issue":"1","key":"10.1016\/j.ejca.2025.116066_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-70044-8","article-title":"Prognostic role of radiological peritoneal cancer index in malignant peritoneal mesothelioma: national cohort study","volume":"10","author":"Salo","year":"2020","journal-title":"Sci Rep"},{"issue":"17","key":"10.1016\/j.ejca.2025.116066_bib31","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: pembrolizumab for the treatment of tumor mutational burden\u2013high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2025.116066_bib32","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: an analysis of all US food and drug administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2025.116066_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103494","article-title":"Pan-cancer analysis of heterogeneity of tumor mutational burden and genomic mutation under treatment pressure","volume":"9","author":"Huang","year":"2024","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.ejca.2025.116066_bib34","doi-asserted-by":"crossref","first-page":"639","DOI":"10.21037\/tlcr-19-485","article-title":"Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma","volume":"9","author":"Brockwell","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ejca.2025.116066_bib35","unstructured":"\u3008https:\/\/clinicaltrials.gov\/study\/NCT04515836?term=mesothelioma&aggFilters=funderType:industry&viewType=Table&rank=9\u3009."},{"issue":"4","key":"10.1016\/j.ejca.2025.116066_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101600","article-title":"Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies","volume":"8","author":"Dietz","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2025.116066_bib37","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.8515","article-title":"Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R\/R) malignant mesothelioma (MM) with BAP1 inactivation","author":"Zauderer","year":"2018","journal-title":"Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116066_bib38","unstructured":"\u3008https:\/\/www.curemeso.org\/2025\/08\/07\/vivace-therapeutics-receives-fda-orphan-drug-designation-for-vt3989-for-mesothelioma-treatment\/#:\u223c:text=Vivace%20Therapeutics%2C%20a%20company%20that,and%20aggressive%20form%20of%20cancer\u3009."},{"issue":"8_ement","key":"10.1016\/j.ejca.2025.116066_bib39","volume":"83","author":"Yap","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2025.116066_bib40","unstructured":"\u3008https:\/\/clinicaltrials.gov\/study\/NCT04665206\u3009."},{"issue":"3","key":"10.1016\/j.ejca.2025.116066_bib41","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S1470-2045(22)00062-6","article-title":"Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial","volume":"23","author":"Fennell","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2025.116066_bib42","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/modpathol.2009.186","article-title":"CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival","volume":"23","author":"Krasinskas","year":"2010","journal-title":"Mod Pathol"},{"issue":"11","key":"10.1016\/j.ejca.2025.116066_bib43","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","article-title":"Genomic landscape of pleural and peritoneal mesothelioma tumours","volume":"127","author":"Hiltbrunner","year":"2022","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2025.116066_bib44","doi-asserted-by":"crossref","first-page":"961","DOI":"10.6004\/jnccn.2023.0045","article-title":"Mesothelioma: peritoneal, version 2.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Ettinger","year":"2023","journal-title":"J Natl Compr Cancer Netw"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925009529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925009529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T17:02:25Z","timestamp":1769792545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925009529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":44,"alternative-id":["S0959804925009529"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116066","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world immunotherapy outcomes in unresectable peritoneal mesothelioma: A French experience","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116066"}}